France’s Enterome Eyes Merger To Make NASDAQ Move

As IBD Pact Is Signed With Nestlé

CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.

NASDAQ
Enterome plots path to Wall Street • Source: Shutterstock

Having inked another deal with Nestle Health Science, microbiome specialist Enterome Bioscience is now weighing up potential merger partners that would give the privately held French firm a listing in the US.

Adopting a reverse merger approach, ie, taking over a biotech that has little to offer other than a market listing, could come back into vogue. The number of crossover rounds – big series B or later financings that bring in institutional investors to support a near-term initial public offering – are in sharp decline, as are IPOs themselves and only one biotech has floated on the European markets so far this year, France's Aelis Farma, which listed on Euronext Paris in February

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business